Compare ASIC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | PHAT |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | 203 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.6M | 894.0M |
| IPO Year | N/A | 2019 |
| Metric | ASIC | PHAT |
|---|---|---|
| Price | $19.57 | $9.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $26.75 | $19.83 |
| AVG Volume (30 Days) | 65.7K | ★ 1.2M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $34.21 | $93.04 |
| Revenue Next Year | $34.65 | $58.91 |
| P/E Ratio | $98.60 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $16.35 | $4.25 |
| 52 Week High | $23.88 | $18.31 |
| Indicator | ASIC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 31.78 |
| Support Level | $18.72 | N/A |
| Resistance Level | $21.09 | $12.83 |
| Average True Range (ATR) | 0.64 | 0.72 |
| MACD | -0.02 | -0.26 |
| Stochastic Oscillator | 23.09 | 2.57 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.